Quoin gets second FDA rare pediatric tag for QRX003
Quoin Pharmaceuticals Ltd. (QNRX) reported that the U.S. FDA has granted Rare Pediatric Disease (RPD) Designation to its lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS).
Rhea-AI Filing Summary
Quoin Pharmaceuticals Ltd. (QNRX) reported that the U.S. FDA has granted Rare Pediatric Disease (RPD) Designation to its lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS). This is the second RPD designation for QRX003, following an earlier RPD designation for Netherton Syndrome.
The RPD program is intended to support development of therapies for serious diseases that primarily affect individuals under 18 years of age. If a New Drug Application for QRX003 is eventually approved, Quoin may qualify to receive a transferable Priority Review Voucher. Quoin also stated that, with an IND cleared by the FDA, it is preparing to initiate a Phase 2 clinical study of QRX003 in PSS before the end of 2026, with plans to enroll up to 12 pediatric and adult patients in the U.S. and Europe.
Positive
- QRX003 received Rare Pediatric Disease Designation from the FDA for Peeling Skin Syndrome, its second RPD designation after Netherton Syndrome, which may qualify Quoin for a Priority Review Voucher if an NDA is approved.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Rare Pediatric Disease Designations for QRX003: 2 designations
Planned Phase 2 PSS trial enrollment: Up to 12 patients
Age focus of RPD program: Under 18 years
+1 more
4 metrics
Rare Pediatric Disease Designations for QRX003
2 designations
RPD status for Netherton Syndrome and for Peeling Skin Syndrome
Planned Phase 2 PSS trial enrollment
Up to 12 patients
Pediatric and adult Peeling Skin Syndrome patients in the U.S. and Europe
Age focus of RPD program
Under 18 years
Diseases primarily affecting individuals under 18 targeted by FDA’s RPD program
Potential Priority Review Voucher
1 voucher
May be granted if an NDA for QRX003 is approved under the RPD program
Key Terms
Rare Pediatric Disease (RPD) Designation, Priority Review Voucher, Investigational New Drug (IND), Peeling Skin Syndrome (PSS), +2 more
6 terms
Rare Pediatric Disease (RPD) Designation regulatory
"the FDA has granted Rare Pediatric Disease (RPD) Designation for QRX003"
A rare pediatric disease (RPD) designation is a regulatory status given to a drug or therapy aimed at treating a serious, uncommon disease that primarily affects children. It matters to investors because the label often brings development incentives—such as faster review, reduced fees, financial support, or market advantages—that lower risk and can speed a product to market, similar to giving a small project a fast pass and extra funding to reach customers sooner.
Priority Review Voucher regulatory
"Quoin may qualify to receive a Priority Review Voucher (PRV)"
A priority review voucher is a transferable regulatory incentive that lets a company move a future drug or device application to the front of the review line, shortening the review period by several months. For investors it matters because the voucher can speed up market access for a high-value product or be sold to other companies for significant cash, acting like a tradable fast-pass that can accelerate revenue or create immediate financial upside.
Investigational New Drug (IND) regulatory
"With the IND cleared by FDA, the Quoin team is preparing"
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.
Peeling Skin Syndrome (PSS) medical
"QRX003, the Company’s lead asset, for the treatment of Peeling Skin Syndrome (PSS)"
Netherton Syndrome medical
"previously granted RPD designation for Netherton Syndrome"
A rare inherited skin and immune disorder that causes fragile, scaly, inflamed skin, frequent infections, and fragile or unusual hair, like a house with faulty waterproofing that lets problems in. For investors, it matters because the small patient population, severe unmet medical need, and predictable biological cause can make treatments eligible for special regulatory incentives, faster development paths, and premium pricing if a safe, effective therapy is approved.
orphan diseases medical
"specialty pharmaceutical company focused on rare and orphan diseases"
Orphan diseases are rare medical conditions that affect a small number of patients compared with common illnesses. For investors, they matter because treatments for these conditions often receive special regulatory incentives—like tax credits, faster review, and market exclusivity—so a successful therapy can win a protected, premium-priced niche market much like a specialized product that serves few customers but commands high margins.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Quoin Pharmaceuticals (QNRX) announce regarding QRX003 in this 8-K?
Quoin announced that the FDA granted Rare Pediatric Disease Designation to its lead asset, QRX003, for the treatment of Peeling Skin Syndrome, marking the second RPD designation for this product after Netherton Syndrome.
How could the FDA Rare Pediatric Disease Designation benefit QNRX financially?
If a New Drug Application for QRX003 is approved, Quoin may qualify to receive a Priority Review Voucher, which can be used for priority review of another application or sold or transferred to another company.
What clinical plans for QRX003 in Peeling Skin Syndrome does QNRX describe?
Quoin states that, with the IND cleared by the FDA, it is preparing to initiate a Phase 2 clinical study before the end of 2026, with plans to enroll up to 12 pediatric and adult PSS patients in the U.S. and Europe.
Why is QRX003’s Rare Pediatric Disease Designation important for QNRX’s pipeline?
The designation supports QRX003’s potential as a therapy for a profoundly underserved pediatric population with Peeling Skin Syndrome and adds to its existing RPD status in Netherton Syndrome, strengthening Quoin’s rare- and orphan-disease portfolio.
What disease areas is Quoin Pharmaceuticals (QNRX) targeting with its pipeline?
Quoin’s pipeline centers on QRX003 and QRX009, which it states may target several rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex and certain vascular and skin malformations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
